

NCI SBIR AND YOUR STATE:

CALIFORNIA



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$144.3 million** in funding across **116 Phase II SBIR/STTR grants** to small businesses in California. The following economic impact estimates quantify the program's contributions to the state's economy:



\$4.5B

IN TOTAL DIRECT SALES



\$9.3B

IN TOTAL ECONOMIC IMPACT



33.8K

JOBS CREATED



\$389.4M

IN STATE & LOCAL TAXES COLLECTED



55

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in California: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$563.2M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

ILLUMINA, INC.

SBIR funding enabled Illumina to develop the Infinium™ genotyping technology. The company has grown to 8,970 employees with more than \$3.5 billion in revenue from the SBIR-awarded project.

SUNESIS PHARMACEUTICALS, INC.

NCI SBIR funds supported Sunesis Pharmaceuticals through early-stage preclinical testing and discovery of tovorafenib for treatment of pediatric low-grade glioma. The technology was ultimately commercialized by Day One Bio, where it has seen \$87.7 million in total revenue marketed as OJEMDA™ across 2,500 patient prescriptions since its launch in April 2024.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.